| CEO Name | Leonard S. Schleifer |
| Nationality | United States |
| Net Worth Estimation | $1.3 billion |
Leonard S. Schleifer's net worth, estimated at around $1.3 billion, primarily derives from his significant equity stake and long-term leadership at Regeneron Pharmaceuticals, Inc., a leading biotech firm. His wealth is further supported by compensation packages and gains from the company's growth in pharmaceutical innovation and stock performance.
Leonard S. Schleifer, CEO of Regeneron Pharmaceuticals, Inc., has an estimated net worth of $1,300,000,000, which is over 1,344% higher than the maximum estimated CEO net worth of $90,000,000 in the healthcare business category. His net worth vastly exceeds both the minimum and maximum benchmarks commonly observed among healthcare CEOs.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Leonard S. Schleifer Performance in Regeneron Pharmaceuticals, Inc.
Leonard S. Schleifer, CEO of Regeneron Pharmaceuticals, Inc., demonstrates visionary leadership by driving innovative drug development and strategic partnerships, significantly advancing the company's pipeline. His decisive, data-driven decision-making has accelerated growth, resulting in multiple FDA approvals and robust financial performance. Schleifer's impact is evident in Regeneron's emergence as a leading biopharmaceutical firm with strong market presence and sustained innovation.
Latest News
Regeneron Pharmaceuticals, Inc. and CEO Leonard Schleifer in Recent News
Regeneron plans to sell a Suffern, NY facility acquired in late 2023 as it focuses on expanding its Tarrytown campus to support its growing R&D pipeline. CEO Leonard Schleifer criticized the pharmaceutical industry for relying on price hikes over true innovation and highlighted Regeneron's successful innovative drugs such as Eylea and Praluent. Schleifer also discussed Regeneron's acquisition bid for 23andMe, addressing privacy concerns and competition issues.
Source: http://rcbizjournal.com/2025/11/03/regeneron-plans-to-sell-former-avon-site-it-purchased-in-2023/